Connect with us

Eyecare

Drug Company Opens US Office to Serve Eyecare Market

mm

Published

on

It formed a subsidiary in MA.

HEIDELBERG, GERMANY — Novaliq GmbH has formed a subsidiary called Novaliq Inc. in Cambridge, MA.

Novaliq GmbH describes itself as “a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology.”

The Cambridge office will be headed by Novaliq’s founder and current chief innovation officer, Bernhard Günther. Günther “ill build the new U.S. organization to leverage the advantages and the potential of the water-free EyeSol drug delivery technology and innovative products in the U.S.,” according to a press release.

“Over the past two years, Novaliq has gained significant momentum,” Günther said. “With the opening of our new U.S. subsidiary, we can better serve the important and growing U.S. eyecare market. I am excited to take on this new challenge and to lead the internationalization of the Novaliq group.”

Advertisement

In the U.S., Novaliq is currently pursuing two late-stage clinical trials in ophthalmology: one for topical CyclASol for the treatment of dry eye disease (DED), and the other to evaluate a compound called NOV03 at two different dosing regimens for evaporative dry eye disease.

“As a leader in DED with first and best-in-class products, we see our role in redefining how this disease is treated,” said Christian Roesky, CEO of Novaliq GmbH. “In the U.S., more than 16 million patients are diagnosed with DED; however, only approximately 10 percent are being treated. This significant gap is a clear indication that new DED therapies are needed. A strong presence in the United States will assist us to better serve this vital pharma market.”

SPONSORED VIDEO

SPONSORED BY VARILUX

The Best Overall Progressive Lens, Now Powered by AI

Engineered with Behavioral Artificial Intelligence and utilizing new XR-motion™ technology, Varilux XR series goes beyond prescription and eye physiology to consider the patient’s visual behavior and design a progressive lens that respects how
their eyes naturally move.

Varilux XR series comes in two versions, Varilux® XR design and Varilux® XR track. The Varilux XR track lens provides an additional level of personalization by incorporating the exclusive Near Vision Behavior Measurement, providing up to 25% more near vision width3 according to the patient’s need, so patients get the highest level of customization.

Discover Varilux XR series and enjoy instantly sharp vision in motion4 and seamless transitions from near to far.

For more information, visit here.

Promoted Headlines

Advertisement

Advertisement

Subscribe

INVISIONMAG.COM
BULLETINS

Get the most important news and business ideas for eyecare professionals every weekday from INVISION.

Advertisement

Advertisement

Most Popular